Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Janux Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 5 | -$0.53 | -$0.26 | -$0.36 |
| Q2 2025 | 2 | -$0.40 | -$0.40 | -$0.40 |
| Q3 2025 | 2 | -$0.45 | -$0.45 | -$0.45 |
| Q4 2025 | 2 | -$0.52 | -$0.52 | -$0.52 |
| Q1 2026 | 1 | -$0.71 | -$0.71 | -$0.71 |
| Q2 2026 | 1 | -$0.77 | -$0.77 | -$0.77 |
| Q3 2026 | 1 | -$0.80 | -$0.80 | -$0.80 |
| Q4 2026 | 1 | -$0.81 | -$0.81 | -$0.81 |
| Q1 2027 | 1 | -$0.60 | -$0.60 | -$0.60 |
| Q2 2027 | 1 | -$0.67 | -$0.67 | -$0.67 |
| Q3 2027 | 1 | -$0.76 | -$0.76 | -$0.76 |
| Q4 2027 | 1 | -$0.87 | -$0.87 | -$0.87 |
Janux Therapeutics, Inc. Earnings Date And Information
Janux Therapeutics, Inc. last posted its earnings results on Thursday, February 27th, 2025. The company reported $-0.36 earnings per share for the quarter, topping analysts' consensus estimates of $-0.49 by $0.13. The company had revenue of 0 for the quarter and had revenue of 10.59 M for the year. Janux Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.28 diluted earnings per share) and currently has a price-to-earnings ratio of -27.08. Janux Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 5th, 2025 based on prior year's report dates.
Janux Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/27/2025 | Q4 2024 | -$0.49 | -$0.36 | 0.13 | $409.92 K | $0 |
| 11/06/2024 | Q3 2024 | -$0.37 | -$0.51 | -0.14 | $1.50 M | $439.00 K |
| 08/07/2024 | Q2 2024 | -$0.32 | -$0.11 | 0.21 | $772.00 K | $8.90 M |
| 05/07/2024 | Q1 2024 | N/A | -$0.30 | N/A | $878.57 K | $1.25 M |
| 03/08/2024 | Q4 2023 | -$0.37 | -$0.25 | 0.12 | $750.00 K | $2.46 M |
| 11/07/2023 | Q3 2023 | -$0.46 | -$0.25 | 0.21 | $845.50 K | $2.52 M |
| 08/08/2023 | Q2 2023 | -$0.52 | -$0.42 | 0.1 | $875.00 K | $1.06 M |
| 05/09/2023 | Q1 2023 | -$0.49 | -$0.42 | 0.07 | $672.35 K | $2.05 M |
| 03/10/2023 | Q4 2022 | -$0.45 | -$0.39 | 0.06 | $805.50 K | $2.85 M |
| 11/10/2022 | Q3 2022 | -$0.51 | -$0.34 | 0.17 | $742.58 K | $1.81 M |
| 08/09/2022 | Q2 2022 | -$0.37 | -$0.40 | -0.03 | $650.00 K | $2.37 M |
| 05/10/2022 | Q1 2022 | -$0.37 | -$0.32 | 0.05 | $810.40 K | $1.59 M |
| 03/18/2022 | Q4 2021 | -$0.30 | -$0.33 | -0.03 | $433.33 K | $1.62 M |
| 11/09/2021 | Q3 2021 | -$0.17 | -$0.26 | -0.09 | $133.33 K | $1.16 M |
| 08/10/2021 | Q2 2021 | -$0.13 | -$0.62 | -0.49 | $133.33 K | $482.00 K |
| 03/30/2021 | Q1 2021 | N/A | -$0.06 | N/A | N/A | $380.00 K |
| 12/30/2020 | Q4 2020 | N/A | -$0.13 | N/A | N/A | $0 |
| 09/29/2020 | Q3 2020 | N/A | -$0.10 | N/A | N/A | $0 |
| 06/29/2020 | Q2 2020 | N/A | -$0.20 | N/A | N/A | $0 |
| 03/30/2020 | Q1 2020 | N/A | -$0.11 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Janux Therapeutics, Inc. Earnings: FAQ's
Janux Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 5th, 2025 based offlast year's report dates.
In the previous quarter, Janux Therapeutics, Inc. (:JANX) reported $-0.36 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.49 by $0.13.
The conference call for Janux Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Janux Therapeutics, Inc.'s latest earnings report can be read online.
Janux Therapeutics, Inc. (:JANX) has a recorded annual revenue of $10.59 M.
Janux Therapeutics, Inc. (:JANX) has a recorded net income of $-68,994,000.Janux Therapeutics, Inc. has generated $-1.28 earnings per share over the last four quarters.
Janux Therapeutics, Inc. (:JANX) has a price-to-earnings ratio of -27.08 and price/earnings-to-growth ratio is 2.88.